JP2014527802A5 - - Google Patents

Download PDF

Info

Publication number
JP2014527802A5
JP2014527802A5 JP2014528901A JP2014528901A JP2014527802A5 JP 2014527802 A5 JP2014527802 A5 JP 2014527802A5 JP 2014528901 A JP2014528901 A JP 2014528901A JP 2014528901 A JP2014528901 A JP 2014528901A JP 2014527802 A5 JP2014527802 A5 JP 2014527802A5
Authority
JP
Japan
Prior art keywords
seq
variable region
chain variable
humanized antibody
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014528901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527802A (ja
JP6096196B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/003819 external-priority patent/WO2013037484A2/en
Publication of JP2014527802A publication Critical patent/JP2014527802A/ja
Publication of JP2014527802A5 publication Critical patent/JP2014527802A5/ja
Application granted granted Critical
Publication of JP6096196B2 publication Critical patent/JP6096196B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014528901A 2011-09-12 2012-09-12 抗αβＴＣＲ抗体 Active JP6096196B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161533510P 2011-09-12 2011-09-12
US61/533,510 2011-09-12
PCT/EP2012/003819 WO2013037484A2 (en) 2011-09-12 2012-09-12 Anti-aplhabetatcr antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017024560A Division JP6599911B2 (ja) 2011-09-12 2017-02-14 抗αβＴＣＲ抗体

Publications (3)

Publication Number Publication Date
JP2014527802A JP2014527802A (ja) 2014-10-23
JP2014527802A5 true JP2014527802A5 (cg-RX-API-DMAC7.html) 2016-11-10
JP6096196B2 JP6096196B2 (ja) 2017-03-15

Family

ID=46851393

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014528901A Active JP6096196B2 (ja) 2011-09-12 2012-09-12 抗αβＴＣＲ抗体
JP2017024560A Active JP6599911B2 (ja) 2011-09-12 2017-02-14 抗αβＴＣＲ抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017024560A Active JP6599911B2 (ja) 2011-09-12 2017-02-14 抗αβＴＣＲ抗体

Country Status (34)

Country Link
US (3) US10017573B2 (cg-RX-API-DMAC7.html)
EP (1) EP2755999B1 (cg-RX-API-DMAC7.html)
JP (2) JP6096196B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140072092A (cg-RX-API-DMAC7.html)
CN (3) CN110272492A (cg-RX-API-DMAC7.html)
AU (2) AU2012307816C1 (cg-RX-API-DMAC7.html)
BR (2) BR112014005644A2 (cg-RX-API-DMAC7.html)
CA (1) CA2847949C (cg-RX-API-DMAC7.html)
CL (2) CL2014000574A1 (cg-RX-API-DMAC7.html)
CO (1) CO6930307A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140127A (cg-RX-API-DMAC7.html)
DK (1) DK2755999T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2014000052A (cg-RX-API-DMAC7.html)
EC (1) ECSP14013307A (cg-RX-API-DMAC7.html)
ES (1) ES2667893T3 (cg-RX-API-DMAC7.html)
GT (1) GT201400045A (cg-RX-API-DMAC7.html)
HU (1) HUE037470T2 (cg-RX-API-DMAC7.html)
IL (2) IL231304B (cg-RX-API-DMAC7.html)
LT (1) LT2755999T (cg-RX-API-DMAC7.html)
MA (1) MA35711B1 (cg-RX-API-DMAC7.html)
MX (2) MX379660B (cg-RX-API-DMAC7.html)
MY (1) MY173924A (cg-RX-API-DMAC7.html)
NI (1) NI201400019A (cg-RX-API-DMAC7.html)
PE (1) PE20141548A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014500408A1 (cg-RX-API-DMAC7.html)
PL (1) PL2755999T3 (cg-RX-API-DMAC7.html)
PT (1) PT2755999T (cg-RX-API-DMAC7.html)
RU (2) RU2630656C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201601738UA (cg-RX-API-DMAC7.html)
TN (1) TN2014000107A1 (cg-RX-API-DMAC7.html)
TW (1) TWI593706B (cg-RX-API-DMAC7.html)
UA (1) UA115533C2 (cg-RX-API-DMAC7.html)
UY (1) UY34317A (cg-RX-API-DMAC7.html)
WO (1) WO2013037484A2 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
SG10201701831VA (en) * 2012-09-12 2017-05-30 Genzyme Corp Fc containing polypeptides with altered glycosylation and reduced effector function
WO2014164534A2 (en) 2013-03-11 2014-10-09 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering
EP3063174B1 (en) * 2013-10-30 2020-12-09 Genzyme Corporation Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
RS64072B1 (sr) 2014-03-19 2023-04-28 Genzyme Corp Mesto-specifični glikoinženjering ciljnih delova
PL3204425T3 (pl) * 2014-10-09 2021-03-08 Genzyme Corporation Glikomodyfikowane koniugaty przeciwciał z lekami
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
EP3303389A1 (en) * 2015-06-01 2018-04-11 Medigene Immunotherapies GmbH T-cell receptor specific antibodies
CN107614519B (zh) * 2015-10-23 2022-08-05 优瑞科生物技术公司 抗体/t细胞受体嵌合构建体及其用途
US20190016804A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
RU2708558C1 (ru) * 2018-12-13 2019-12-09 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоопухолевой иммунологической защиты к клеткам лимфомы EL-4
SG11202108955QA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Antibody molecules that bind to nkp30 and uses thereof
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
CN113939534B (zh) * 2019-04-03 2025-02-28 建新公司 具有降低的断裂的抗αβTCR结合多肽
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
CN113122503B (zh) * 2019-12-30 2022-10-11 博雅缉因（北京）生物科技有限公司 一种靶向t细胞淋巴瘤细胞的通用型car-t及其制备方法和应用
CN113122504A (zh) * 2019-12-30 2021-07-16 博雅辑因（北京）生物科技有限公司 一种纯化ucart细胞的方法与应用
WO2021136415A1 (zh) * 2019-12-30 2021-07-08 博雅辑因（北京）生物科技有限公司 一种纯化ucart细胞的方法与应用
GB2609554B (en) * 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
CN113088495B (zh) * 2020-01-09 2024-08-16 苏州方德门达新药开发有限公司 工程改造的t细胞、其制备及应用
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023012899A (es) 2021-05-05 2023-11-08 Immatics Biotechnologies Gmbh Polipeptidos de union a antigeno bma031 mejorados.
CN119233999A (zh) * 2022-05-25 2024-12-31 羿尊生物医药（浙江）有限公司 靶向细胞膜受体蛋白的融合蛋白及其应用

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5149782A (en) 1988-08-19 1992-09-22 Tanox Biosystems, Inc. Molecular conjugates containing cell membrane-blending agents
ATE159982T1 (de) 1988-09-15 1997-11-15 Univ Columbia Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5792456A (en) 1994-08-04 1998-08-11 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
EP0706799B1 (en) 1994-09-16 2001-11-14 MERCK PATENT GmbH Immunoconjugates II
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
UA71889C2 (uk) 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
ATE386809T1 (de) 1996-08-02 2008-03-15 Bristol Myers Squibb Co Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6953675B2 (en) 1997-11-06 2005-10-11 Immunomedics, Inc. Landscaped antibodies and antibody fragments for clinical use
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1115740A1 (en) 1998-09-23 2001-07-18 The Regents of the University of California Synthetic peptides, conjugation reagents and methods
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
CN1110322C (zh) 1999-07-21 2003-06-04 中国医学科学院医药生物技术研究所 单克隆抗体Fab'－平阳霉素偶联物及其抗肿瘤作用
EP1294904A1 (en) 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20050107595A1 (en) 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7657380B2 (en) 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
ATE536188T1 (de) 2002-08-14 2011-12-15 Macrogenics Inc Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
EP1562972B1 (en) 2002-10-15 2010-09-08 Facet Biotech Corporation ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
UA87458C2 (ru) 2003-06-12 2009-07-27 Елі Ліллі Енд Компані Гибридные белки-аналоги glp-1
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
RU2392324C2 (ru) * 2003-09-18 2010-06-20 Симфоген А/С Способ связывания интересующих последовательностей
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US7001978B2 (en) 2003-11-19 2006-02-21 Xerox Corporation Unsaturated ester substituted polymers with reduced halogen content
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
PL1706424T3 (pl) 2004-01-12 2010-04-30 Mentrik Biotech Llc Warianty regionu Fc
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
RU2006138181A (ru) 2004-05-04 2008-06-10 Ново Нордиск Хелс Кеа Аг (Ch) О-связанные гликоформы полипептидов и способ их изготовления
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
CA2565961A1 (en) 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
JP2008537874A (ja) 2004-09-27 2008-10-02 セントカー・インコーポレーテツド ｓＲＡＧＥミメティボディ、組成物、方法および使用
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
JP4829609B2 (ja) * 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
DK1866339T3 (da) * 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
EP1871808A2 (en) 2005-03-31 2008-01-02 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
JP2008537941A (ja) 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
ES2523666T3 (es) 2005-05-31 2014-11-28 Board Of Regents, The University Of Texas System Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos
AU2006261127B2 (en) 2005-06-17 2012-03-15 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
CN101506238B (zh) 2005-06-30 2013-11-06 森托科尔公司 具有提高治疗活性的方法和成分
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CZ2005627A3 (cs) 2005-10-03 2006-09-13 Flek@Jaroslav Zubní kartácek
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
EP2041180B8 (en) * 2006-06-19 2014-03-05 Liquidating Trust Ilt3 binding molecules and uses therefor
FI20060946A0 (fi) 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
JP2010512306A (ja) 2006-10-27 2010-04-22 ザ ロックフェラー ユニバーシティー 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
CA2674603C (en) 2007-01-09 2016-03-29 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
JP5357778B2 (ja) 2007-01-23 2013-12-04 ゼンコー・インコーポレイテッド 最適化ｃｄ４０抗体および前記を使用する方法
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
WO2009045894A1 (en) 2007-09-28 2009-04-09 Centocor, Inc. Methods and structural conformations of antibody preparations with increased resistance to proteases
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
MX2010003718A (es) 2007-10-19 2010-04-21 Genentech Inc Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
CA2711503A1 (en) 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
UA106586C2 (uk) 2008-01-31 2014-09-25 Дженентек, Інк. Анти-cd79b антитіла, і імунокон'югати та способи їх застосування
US20110137011A1 (en) 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
UA40611U (ru) 2008-05-26 2009-04-27 Владимир Семенович Живченко Способ десульфурации железоуглеродистого расплава в тигельной печи
JP2012501178A (ja) * 2008-08-26 2012-01-19 マクロジェニクス，インコーポレーテッド Ｔ細胞受容体抗体およびその使用方法
EP2233499A1 (en) 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
EP2982380B1 (en) * 2010-03-04 2021-09-01 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
BR112013003095B1 (pt) 2010-08-10 2023-03-28 Glycotope Gmbh Método para controle da meia-vida em circulação de um anticorpo ou um fragmento ou derivado funcional do mesmo, composições de anticorpo, seu usos e seus métodos de produção
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
CN107088225A (zh) 2011-03-11 2017-08-25 阿米库斯治疗学公司 治疗法布里病的给药方案
TWI838039B (zh) 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
SG10201701831VA (en) 2012-09-12 2017-05-30 Genzyme Corp Fc containing polypeptides with altered glycosylation and reduced effector function
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
WO2014164534A2 (en) 2013-03-11 2014-10-09 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering
RS64072B1 (sr) 2014-03-19 2023-04-28 Genzyme Corp Mesto-specifični glikoinženjering ciljnih delova
CA2944539A1 (en) 2014-04-08 2015-10-15 University Of Georgia Research Foundation, Inc. Site-specific antibody-drug glycoconjugates and methods
PL3204425T3 (pl) 2014-10-09 2021-03-08 Genzyme Corporation Glikomodyfikowane koniugaty przeciwciał z lekami
US10280317B2 (en) 2016-07-07 2019-05-07 Northwestern University Enhanced conductivity, adhesion and environmental stability of printed graphene inks with nitrocellulose

Similar Documents

Publication Publication Date Title
JP2014527802A5 (cg-RX-API-DMAC7.html)
JP2018121657A5 (cg-RX-API-DMAC7.html)
Mehta et al. An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA
Borrok et al. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling
JP7089470B2 (ja) 抗体およびその使用方法
JP2015535820A5 (cg-RX-API-DMAC7.html)
JP2014518883A5 (cg-RX-API-DMAC7.html)
WO2008017963A3 (en) Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
WO2006082515A3 (en) Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
CY1120252T1 (el) Μορια δεσμευσης αντιγονου με αυξημενη συγγενεια προσδεσης στον υποδοχεα fc και λειτουργια τελεστη
IN2015DN01361A (cg-RX-API-DMAC7.html)
EP4477671A3 (en) Humanized universal light chain mice
EP4342995A3 (en) Methods for controlling blood pharmacokinetics of antibodies
JP2020500510A5 (cg-RX-API-DMAC7.html)
JP2016507525A5 (cg-RX-API-DMAC7.html)
Zhang et al. Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization
JP2018519296A5 (cg-RX-API-DMAC7.html)
PH12012502376A1 (en) Modified antigen binding molecules with altered cell signaling activity
IL276286B1 (en) FC variants with improved binding to FCRN and extended half-life
CA2849765C (en) Hybrid constant regions
JP2017505121A5 (cg-RX-API-DMAC7.html)
AR084210A1 (es) PROTEINAS DE UNION AL TNF-a
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
JP2016507523A5 (cg-RX-API-DMAC7.html)
JP2012515556A5 (cg-RX-API-DMAC7.html)